Stay updated with breaking news from Xiaoting Zhang. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A University of Cincinnati Venture Lab-backed startup is developing a breast cancer treatment that may be more effective with fewer side effects thanks to RNA nanotechnology that is similar to what was used to produce COVID-19 vaccines.
A grant renewal for a University of Cincinnati researcher will help continue the study of genetic drivers of breast cancer and potential therapeutic targets.
"According to the American Cancer Society's estimate, over 280,000 new cases of invasive breast cancer will be diagnosed in women in 2021," explains Xiaoting Zhang, PhD, professor and Thomas Boat Endowed Chair in UC's Department of Cancer Biology, director of the Breast Cancer Research Program and member of the University of Cincinnati Cancer Center, who led this research. "Like many other cancers, breast cancer cells are fueled by mutations and overproduction of 'driver' genes, which lead the process of cancer development." He says one of these genes, called HER2 (human epidermal growth fact...